Loading…
Product attributes as listed by the labeler in the FDA NDC Directory.
FDA pharmacologic class: Ergolines [CS]; Ergot Derivative [EPC]
Also searchable as: Cabergoline
Drug codes appear here only when a CMS NDC–HCPCS crosswalk lists at least one of this drug’s NDC packages. CodeRx never assigns a code from the name or ingredient.
Cabergoline, oral, 0.25 mg
Derived: 1 of 1 NDC package(s) for this drug appear in the CMS NDC–HCPCS crosswalk for J8515. CMS quarters Q2 2026 – Q4 2026
J-codes are permanent national codes for drugs and biologicals — most often clinician-administered (buy-and-bill) products paid under Medicare Part B — plus certain immunosuppressive, inhalation (via DME), and oral anticancer/antiemetic drugs. Units are reported in multiples of the dosage in the code descriptor.
Package NDCs from the FDA directory, normalized to the 11-digit 5-4-2 format used on claims.
| 11-digit NDC | FDA NDC | Package description | Strength · form | Labeler | HCPCS · units / NDC | Status |
|---|---|---|---|---|---|---|
| 69238-2693-01 | 69238-2693-1 | 8 TABLET in 1 BOTTLE (69238-2693-1) | .5 mg/1Tablet | Amneal Pharmaceuticals NY LLC | J8515 · 16 units |
One HCPCS billing unit of J8515
0.25 MG
Medicare payment limit per unit (Q4 2026): $0.337
Billable units per package for each NDC are listed in the NDC packages table above (CMS “BILLUNITSPKG”).
Medicare Part B payment limits for the codes above, then how the home infusion per diem S-codes are paid. Commercial payer rates, AWP, and WAC are not included.
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $0.337 | 0.25 MG | 20% | +11.6% |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Which Medicare benefit pays for this drug?
ICD-10-CM codes that Medicare contractors' Billing and Coding articles list as supporting medical necessity for this drug's HCPCS codes — covered diagnoses, not how often each is used. Washington (Noridian JF) articles come first; other contractors' articles are linked below.
No current Medicare Billing and Coding article lists J8515.
Quarterly changes to the HCPCS codes linked to this drug.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jan 1, 2006 |
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
When a home infusion pharmacy dispenses this drug, the drug is billed with the code above and each day of pharmacy services, supplies, and equipment with a per diem S-code. CMS publishes no drug-to-per-diem crosswalk, so CodeRx picks the therapy category from the FDA pharmacologic class and route. S-codes are not payable by Medicare; confirm the code against the payer contract.
Home infusion per diems apply to infused or injected therapy; FDA lists this drug’s route(s) as oral.
| — |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $0.302 | 0.25 MG | 20% | +96.1% | — |
|---|
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $0.154 | 0.25 MG | 20% | — | Added April 2026 |
|---|
No home infusion per diem applies to this drug (see HCPCS coding above).
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Every import with its checksum is listed on the data sources page.